Compound: oseltamivir
SMILES: O=C(OCC)C1=C[C@@H](OC(CC)CC)[C@H](NC(=O)C)[C@H](C1)N
InChIKey: VSZGPKBBMSAYNT-RRFJBIMHSA-N
Synonyms: oseltamivir, 196618-13-0, Tamvir, (-)-oseltamivir, GS-4104, ebilfumin, GS 4104, oseltamivirum, GS4104, HSDB 7433, ethyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate, Ro-640796, Ro-64-0796, Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate, Ro 640796, GS-4071 ETHYL ESTER, 20O93L6F9H, 1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R-(3alpha,4beta,5alpha))-, ethyl (3R,4R,5S)-5-amino-4-acetamido-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate, RO64-0796, CHEBI:7798, DTXSID9044291, 1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R,4R,5S)-, ethyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxy-cyclohexene-1-carboxylate, RefChem:6086, DTXCID7024291, J05AH02, Tamiflu-Free, (3R,4R,5S)-Ethyl 4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-enecarboxylate, Oseltamivir (INN), MFCD00953939, Oseltamivir 100 microg/mL in Acetonitrile, OSELTAMIVIR [INN], Oseltamivir [INN:BAN], ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)cyclohexene-1-carboxylate, Agucort (TN), Tamiflu (*Phosphate salt 1:1*), UNII-20O93L6F9H, SR-05000001499, oseltamivir-phosphate, GOP-A-Flu, Oseltamivir (Standard), OSELTAMIVIR [MI], GS 4104;GOP-A-Flu;GS-4104;Tamiflu-Free;Tamvir, OSELTAMIVIR [HSDB], OSELTAMIVIR [VANDF], CHEMBL1229, SCHEMBL32035, OSELTAMIVIR [WHO-DD], BIDD:GT0426, OSELTAMIVIR [EMA EPAR], BDBM5025, orb2281185, GTPL11427, VSZGPKBBMSAYNT-RRFJBIMHSA-N, HMS2090C11, EX-A3415, MSK10083, EBC-26742, HY-13317R, AKOS015843442, AKOS015960501, CS-0552, DB00198, DT-0013, FO61474, ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate, Ethyl (5S,3R,4R)-4-(acetylamino)-5-amino-3-(ethylpropoxy)cyclohex-1-enecarboxylate, NCGC00095191-06, NCGC00095191-12, NCGC00095191-14, NCGC00095191-16, NCGC00178698-01, NCGC00178698-02, NCGC00178698-04, HY-13317, RO640796, NS00000301, O0591, C08092, D08306, E84533, AB00173476-02, AB00173476_04, AR-270/43507961, Q211509, SR-05000001499-1, BRD-K76011241-001-01-8, BRD-K76011241-001-02-6, BRD-K76011241-011-02-5, BRD-K76011241-045-01-5, Oseltamivir Phosphate Working Standard (Secondary Reference Standard), Ethyl (3R, 4R, 5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate, ethyl (3r,4r,5s)-4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate, Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-[(pentan-3-yl)oxy]cyclohex-1-ene-1-carboxylate, ethyl 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate, rel-Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate, (3r,4r,5s)-4-acetylamino-5-amino-3(1-ethylpropoxy) -1-cyclohexene-1-carboxylic acid ethyl ester, (3R,4R,5S)-4-acetylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid ethyl ester, (3R,4R,5S)-4-acetylamino-5-amino-3-(1-ethyl-propoxy)cyclohex-1-enecarboxylic acid ethyl ester, 182367-47-1
Theoretical properties:
molecular_formula: C16H28N2O4
molecular_weight: 312.40 g/mol
exact_mass: 312.20490738 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 5
rotatable_bond_count: 8
heavy_atom_count: 22
topological_polar_surface_area: 90.7 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
solubility: Soluble
Descriptions:
{"pubchem": "Oseltamivir is a cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza. It has a role as a xenobiotic, an antiviral drug, a prodrug, an EC 3.2.1.18 (exo-alpha-sialidase) inhibitor and an environmental contaminant. It is a member of acetamides, a cyclohexenecarboxylate ester, an amino-acid ester and a primary amino compound.", "chebi": "A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza.", "chembl": "OSELTAMIVIR is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.", "wikipedia": "Oseltamivir, sold under the brand name Tamiflu among others, is an antiviral medication used to treat and prevent influenza A and influenza B, viruses that cause the flu. Many medical organizations recommend it in people who have complications or are at high risk of complications within 48 hours of first symptoms of infection. They recommend it to prevent infection in those at high risk, but not the general population. The Centers for Disease Control and Prevention (CDC) recommends that clinicians use their discretion to treat those at lower risk who present within 48 hours of first symptoms of infection. It is taken by mouth, either as a pill or liquid.\nRecommendations regarding oseltamivir are controversial as are criticisms of the recommendations. A 2014 Cochrane Review concluded that oseltamivir does not reduce hospitalizations, and that there is no evidence of reduction in complications of influenza. Two meta-analyses have concluded that benefits in those who are otherwise healthy do not outweigh its risks. They also found little evidence regarding whether treatment changes the risk of hospitalization or death in high risk populations. However, another meta-analysis found that oseltamivir was effective for prevention of influenza at the individual and household levels.\nCommon side effects include vomiting, diarrhea, headache, and trouble sleeping. Other side effects may include psychiatric symptoms and seizures. In the United States, it is recommended for influenza infections during pregnancy. It has been taken by a small number of pregnant women without signs of problems. Dose adjustment may be needed in those with kidney problems.\nOseltamivir was approved for medical use in the US in 1999. It was the first neuraminidase inhibitor available by mouth. It is on the World Health Organization's List of Essential Medicines but was downgraded to \"complementary\" status in 2017. A generic version was approved in the US in 2016. In 2023, it was the 250th most commonly prescribed medication in the United States, with more than 1 million prescriptions."}